| Growth failure
Genotropin vs Increlex
Side-by-side clinical, coverage, and cost comparison for growth failure.Deep comparison between: Genotropin vs Increlex with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsIncrelex has a higher rate of injection site reactions vs Genotropin based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Increlex but not Genotropin, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Genotropin
Increlex
At A Glance
SC injection
6-7 times weekly
Recombinant human growth hormone
SC injection
Twice daily
Recombinant human IGF-1 (rhIGF-1)
Indications
- Somatotropin deficiency
- Prader-Willi Syndrome
- Growth failure
- Turner Syndrome
- Growth Disorders
- Growth failure
- Insulin-Like Growth Factor I Deficiency
Dosing
Somatotropin deficiency (pediatric) 0.16 to 0.24 mg/kg/week SC, divided into 6-7 subcutaneous injections.
Prader-Willi Syndrome 0.24 mg/kg/week SC, divided into 6-7 subcutaneous injections.
Turner Syndrome 0.33 mg/kg/week SC, divided into 6-7 subcutaneous injections.
Growth Disorders Up to 0.47 mg/kg/week SC (idiopathic short stature), divided into 6-7 subcutaneous injections.
Growth failure Up to 0.48 mg/kg/week SC (born small for gestational age), divided into 6-7 subcutaneous injections.
Somatotropin deficiency (adult) Non-weight based: starting ~0.2 mg/day SC (range 0.15-0.30 mg/day), titrated by 0.1-0.2 mg/day increments; weight based: starting up to 0.04 mg/kg/week SC, titrated to up to 0.08 mg/kg/week.
Growth failure, Insulin-Like Growth Factor I Deficiency Starting dose 0.04 to 0.08 mg/kg twice daily by SC injection; if well-tolerated for at least one week, may increase by 0.04 mg/kg per dose to a maximum of 0.12 mg/kg twice daily; administer shortly before or after (+/- 20 minutes) a meal or snack.
Contraindications
- Acute critical illness due to complications following open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
- Prader-Willi syndrome with severe obesity, history of upper airway obstruction or sleep apnea, or severe respiratory impairment
- Active malignancy
- Known hypersensitivity to somatropin or any excipient
- Active proliferative or severe non-proliferative diabetic retinopathy
- Closed epiphyses (for growth promotion in pediatric patients)
- Known hypersensitivity to mecasermin or any inactive ingredient in INCRELEX
- Closed epiphyses
- Malignant neoplasia or history of malignancy
Adverse Reactions
Most common (>=5%) Peripheral swelling, arthralgia, upper respiratory infection, pain in extremities, peripheral edema, paresthesia, headache, stiffness of extremities, fatigue (reported in adult GHD clinical trials at or above 5% threshold)
Serious Increased mortality in acute critical illness, fatalities in Prader-Willi syndrome, neoplasms, glucose intolerance and diabetes mellitus, intracranial hypertension, severe hypersensitivity, fluid retention, hypoadrenalism, hypothyroidism, slipped capital femoral epiphysis, scoliosis progression, otitis media and cardiovascular disorders in Turner syndrome, pancreatitis
Postmarketing Serious systemic hypersensitivity reactions including anaphylaxis and angioedema, leukemia, new-onset type 2 diabetes mellitus, slipped capital femoral epiphysis, osteonecrosis/avascular necrosis, carpal tunnel syndrome
Most common (>=5%) Hypoglycemia, lipohypertrophy, bruising, otitis media, serous otitis media, snoring, tonsillar hypertrophy, headache, dizziness, convulsions, vomiting, hypoacusis, fluid in middle ear, ear pain, abnormal tympanometry, cardiac murmur, arthralgia, pain in extremity, thymus hypertrophy
Serious Hypoglycemia, hypersensitivity and allergic reactions including anaphylaxis, intracranial hypertension, tonsillar and adenoidal hypertrophy, slipped capital femoral epiphysis, progression of preexisting scoliosis, malignant neoplasia
Postmarketing Anaphylaxis, generalized urticaria, angioedema, dyspnea, injection site reactions, alopecia, hair texture abnormality, osteonecrosis/avascular necrosis, neoplasms
Pharmacology
Somatropin, a recombinant human growth hormone therapeutically equivalent to pituitary-derived GH, stimulates linear growth in pediatric patients through effects on epiphyseal plates, normalizes IGF-I concentrations in GHD and Prader-Willi syndrome, and in adults reduces fat mass and increases lean body mass with favorable lipid metabolic changes.
Recombinant human IGF-1 (rhIGF-1) that activates the Type 1 IGF-1 receptor in target tissues, stimulating intracellular signaling leading to statural growth; also suppresses hepatic glucose production and stimulates peripheral glucose utilization, giving it a hypoglycemic potential.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Genotropin
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (4/12) · Qty limit (10/12)
Increlex
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Genotropin
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Increlex
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Genotropin
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Increlex
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Growth Hormone Deficiency
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableHealthWell: Amyotrophic Lateral Sclerosis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
GenotropinView full Genotropin profile
IncrelexView full Increlex profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.